Research programme: complement component 3a (C3a) receptor modulators - UniQuest
Latest Information Update: 13 Sep 2023
At a glance
- Originator University of Queensland
- Developer UniQuest; University of Queensland
- Class Small molecules
- Mechanism of Action Complement C3 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Inflammation; Metabolic disorders
Most Recent Events
- 13 Sep 2023 Preclinical development for Inflammation is ongoing in Australia (UniQuest website, September 2023)
- 13 Sep 2023 Preclinical development for Metabolic-disorders is ongoing in Australia (UniQuest website, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Inflammation in Australia (PO)